Servi J. C. Stevens

Servi J. C. Stevens

Auto-generated profile, based on publicly available information

Servi J. C. Stevens

Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in Nature Neuroscience
Verified
Journal Article
Closed access
SLStefan H Lelieveld
Stefan H Lelieveld
MRMargot R F Reijnders
Margot R F Reijnders
RPRolph Pfundt
Rolph Pfundt
HYHelger G Yntema
Helger G Yntema
EKErik-Jan Kamsteeg
Erik-Jan Kamsteeg
CGChristian Gilissen
Christian Gilissen

1 December 2019 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
KMKaruna R.M. van der Meij
Karuna R.M. van der Meij
ESErik Sistermans
Erik Sistermans
MMMerryn V.E. Macville
Merryn V.E. Macville
SSServi J.C. Stevens
Servi J.C. Stevens
CBCaroline J. Bax
Caroline J. Bax
MWMarjan M. Weiss
Marjan M. Weiss

1 March 2001 in Blood
Verified
Journal Article
Closed access
SSServi J. C. Stevens
Servi J. C. Stevens
EVErik A. M. Verschuuren
Erik A. M. Verschuuren
IPInge Pronk
Inge Pronk
WBWim van der Bij
Wim van der Bij
MHMartin Harmsen
Martin Harmsen
JMJaap Middeldorp
Jaap Middeldorp
Posttransplant lymphoproliferative disease (PTLD) is a frequent and severe Epstein-Barr virus (EBV)–associated complication in transplantation recipients that is caused by iatrogenic suppression of T-cell function. The diagnostic value of weekly EBV DNA load monitoring was investigated in prospectively collected unfractionated whole blood and serum samples of lung transplantation (LTx) recipients with and without PTLD. In PTLD patients, 78% of tested whole blood samples were above the cut-off value of quantitative competitive polymerase chain reaction (Q-PCR) (greater than 2000 EBV DNA copies per mL blood), with the majority of patients having high viral loads before and at PTLD diagnosis. Especially in a primary EBV-infected patient and in patients with conversion of immunosuppressive treatment, rapid increases in peripheral blood EBV DNA load diagnosed and predicted PTLD. In non-PTLD transplantation recipients, only 3.4% of the whole blood samples was above the cut-off value (P < .0001) despite heavy immune suppression and cytomegalovirus (CMV)-related disease. These findings illustrate the clinical importance of frequent EBV DNA load monitoring in LTx recipients. The increased EBV DNA loads in PTLD patients were restricted to the cellular blood compartment, as parallel serum samples were all below cut-off value, which indicates absence of lytic viral replication. EBV+ cells in PTLD patients have a very short doubling time, which can be as low as 56 hours, thereby creating the need for high screening frequency in high-risk patients. Furthermore, it is shown that EBV and CMV can reactivate independently in LTx recipients and that EBV DNA load monitoring may be useful in discriminating PTLD from rejection.

1 June 2017 in Genetics in Medicine
Verified
Journal Article
Open access
RPRolph Pfundt
Rolph Pfundt
MRMarisol del Rosario
Marisol del Rosario
LVLisenka E.L.M. Vissers
Lisenka E.L.M. Vissers
MKMichael P. Kwint
Michael P. Kwint
IJIrene M. Janssen
Irene M. Janssen
JHJayne Hehir
Jayne Hehir
Copy-number variation is a common source of genomic variation and an important genetic cause of disease. Microarray-based analysis of copy-number variants (CNVs) has become a first-tier diagnostic test for patients with neurodevelopmental disorders, with a diagnostic yield of 10-20%. However, for most other genetic disorders, the role of CNVs is less clear and most diagnostic genetic studies are generally limited to the study of single-nucleotide variants (SNVs) and other small variants. With the introduction of exome and genome sequencing, it is now possible to detect both SNVs and CNVs using an exome- or genome-wide approach with a single test. We performed exome-based read-depth CNV screening on data from 2,603 patients affected by a range of genetic disorders for which exome sequencing was performed in a diagnostic setting. In total, 123 clinically relevant CNVs ranging in size from 727 bp to 15.3 Mb were detected, which resulted in 51 conclusive diagnoses and an overall increase in diagnostic yield of ~2% (ranging from 0 to -5.8% per disorder). This study shows that CNVs play an important role in a broad range of genetic disorders and that detection via exome-based CNV profiling results in an increase in the diagnostic yield without additional testing, bringing us closer to single-test genomics.Genet Med advance online publication 27 October 2016.

1 March 2016 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
HSHolly A.F. Stessman
Holly A.F. Stessman
MWMarjolein H. Willemsen
Marjolein H. Willemsen
MFMichaela Fenckova
Michaela Fenckova
OPOsnat Penn
Osnat Penn
AHAlexander Hoischen
Alexander Hoischen
TKTjitske Kleefstra
Tjitske Kleefstra

1 November 2014 in Genetics in Medicine
Verified
Journal Article
Open access
SNSenthilkumar A. Natesan
Senthilkumar A. Natesan
ABAlex J. Bladon
Alex J. Bladon
SCSerdar Coskun
Serdar Coskun
WQWafa Qubbaj
Wafa Qubbaj
RPRenata Prates
Renata Prates
AHAlan H. Handyside
Alan H. Handyside
Our aim was to compare the accuracy of family- or disease-specific targeted haplotyping and direct mutation-detection strategies with the accuracy of genome-wide mapping of the parental origin of each chromosome, or karyomapping, by single-nucleotide polymorphism genotyping of the parents, a close relative of known disease status, and the embryo cell(s) used for preimplantation genetic diagnosis of single-gene defects in a single cell or small numbers of cells biopsied from human embryos following in vitro fertilization. Genomic DNA and whole-genome amplification products from embryo samples, which were previously diagnosed by targeted haplotyping, were genotyped for single-nucleotide polymorphisms genome-wide detection and retrospectively analyzed blind by karyomapping. Single-nucleotide polymorphism genotyping and karyomapping were successful in 213/218 (97.7%) samples from 44 preimplantation genetic diagnosis cycles for 25 single-gene defects with various modes of inheritance distributed widely across the genome. Karyomapping was concordant with targeted haplotyping in 208 (97.7%) samples, and the five nonconcordant samples were all in consanguineous regions with limited or inconsistent haplotyping results. Genome-wide karyomapping is highly accurate and facilitates analysis of the inheritance of almost any single-gene defect, or any combination of loci, at the single-cell level, greatly expanding the range of conditions for which preimplantation genetic diagnosis can be offered clinically without the need for customized test development.